相关实验视频
Updated: Sep 12, 2025

08:18
High-throughput Nitrobenzoxadiazole-labeled Cholesterol Efflux Assay
Published on: January 7, 2019
9.2K
福西托B及其衍生物作为新型ASGR1抑制剂,用于增强胆固醇效流
Manru Ma1, Rongfeng Liu2, Yan Liu1
1Department of Pharmacology, School of Pharmacy, Qingdao Medical College of Qingdao University, Qingdao, China.
Chemistry & biodiversity
|August 6, 2025
概括
福西酸乙及其衍生物通过抑制亚亚糖蛋白受体1 (ASGR1) 有效地促进胆固醇排放. 这项研究提供了针对ASGR1介导的胆固醇调节的代谢性疾病的潜在新疗法.
科学领域:
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
- 代谢性疾病研究研究.
背景情况:
- 亚洲糖蛋白受体1 (ASGR1) 是代谢疾病的关键点,因为它在胆固醇流失中的作用.
- 福西B (FB) 是一种具有已知的脂质调节作用的天然化合物.
- 目前尚不清楚FB和ASGR1在胆固醇调节中的相互作用.
研究的目的:
- 研究福西B (FB) 和其衍生物作为新型ASGR1抑制剂.
- 评估它们在肝细胞中促进胆固醇排放的潜力 (Huh-7).
- 为开发ASGR1向的降胆固醇疗法奠定基础.
主要方法:
- 对ASGR1抑制的FB及其衍生物的系统评估.
- 在Huh-7细胞中促进胆固醇外流的评估.
- 细胞活力测试以确认安全性.
- 机理学研究以阐明作用模式.
主要成果:
- FB和七种衍生品显著增强了胆固醇排放量,以剂量依赖的方式.
- 没有观察到对细胞活力的不良影响.
- 证实这些化合物可以抑制ASGR1活性.
- 这种机制涉及直接抑制ASGR1.
结论:
- 福西B及其衍生物是有效的ASGR1抑制剂.
- 这些化合物有望促进胆固醇排放.
- 这项研究为开发ASGR1向的降胆固醇治疗提供了候选分子.
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
873
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
873
Cholesterol: Significance and Regulation
687
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Considering cholesterol and...
687
Lipid Absorption
734
Dietary triglycerides from chyme in the duodenum are mixed with bile salts produced by the liver to emulsify fats. As a result, large droplets are broken down into smaller ones, increasing the surface area for enzymatic action. Once emulsified, pancreatic lipases hydrolyze the triglycerides into free fatty acids and monoglycerides.
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
734
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
402
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
402
Membrane Asymmetry Regulating Transporters
4.9K
Enzymes like flippase, floppase, and scramblase transfer phospholipids from one layer to another in the membrane, thereby affecting membrane asymmetry.
Flippase
Eukaryotic flippases are type-IV P-type ATPases or P4-ATPases belonging to P-type ATPase family proteins that are membrane-bound pumps involved in the ATP-mediated transport of ions and molecules across the membrane. Flippases flip specific phospholipids from the outer to the inner leaflet of a membrane. All P4-ATPases have one...
Flippase
Eukaryotic flippases are type-IV P-type ATPases or P4-ATPases belonging to P-type ATPase family proteins that are membrane-bound pumps involved in the ATP-mediated transport of ions and molecules across the membrane. Flippases flip specific phospholipids from the outer to the inner leaflet of a membrane. All P4-ATPases have one...
4.9K
Atherosclerosis III: Management
35
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
35

